Perspective Therapeutics (CATX) Depreciation & Amortization (CF) (2016 - 2026)
Perspective Therapeutics' Depreciation & Amortization (CF) history spans 17 years, with the latest figure at $1.1 million for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 53.83% to $1.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.6 million, a 35.91% increase, with the full-year FY2025 number at $3.3 million, up 40.98% from a year prior.
- Depreciation & Amortization (CF) hit $1.1 million in Q1 2026 for Perspective Therapeutics, up from $1.0 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for CATX hit a ceiling of $1.1 million in Q1 2026 and a floor of $67000.0 in Q3 2022.
- Historically, Depreciation & Amortization (CF) has averaged $473117.6 across 5 years, with a median of $356000.0 in 2024.
- Biggest five-year swings in Depreciation & Amortization (CF): grew 13.56% in 2022 and later skyrocketed 286.57% in 2023.
- Tracing CATX's Depreciation & Amortization (CF) over 5 years: stood at $138000.0 in 2022, then surged by 118.84% to $302000.0 in 2023, then soared by 134.77% to $709000.0 in 2024, then soared by 42.6% to $1.0 million in 2025, then rose by 11.37% to $1.1 million in 2026.
- Business Quant data shows Depreciation & Amortization (CF) for CATX at $1.1 million in Q1 2026, $1.0 million in Q4 2025, and $775000.0 in Q3 2025.